The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma.
 
Clara Steiner
No Relationships to Disclose
 
Eddy Saad
Research Funding - Genentech/Roche (Inst); Oncohost
 
Renee Maria Saliby
Honoraria - MashupMD
 
Marc Eid
No Relationships to Disclose
 
Karl Semaan
No Relationships to Disclose
 
Marc Machaalani
No Relationships to Disclose
 
Emre Yekeduz
No Relationships to Disclose
 
Jack Horst
No Relationships to Disclose
 
Jasmine Lee
No Relationships to Disclose
 
Noa Phillips
No Relationships to Disclose
 
Rachel Trowbridge
No Relationships to Disclose
 
Marta Pirovano
No Relationships to Disclose
 
Carolina Saldanha Neves Horta Lima
No Relationships to Disclose
 
Shruti Gupta
Honoraria - Springer Inc.
Consulting or Advisory Role - Alexion Pharmaceuticals; Proletariat Therapeutics; Secretome
Research Funding - AstraZeneca; BTG; GE Healthcare; Janssen
 
Gwo-Shu Lee
No Relationships to Disclose
 
Yehonatan Elon
Employment - Oncohost
Leadership - Oncohost
Stock and Other Ownership Interests - Oncohost
Patents, Royalties, Other Intellectual Property - Plasma proteomics based predictor for response to immune checkpoint inhibitors
 
Adam Dicker
Stock and Other Ownership Interests - Oncohost
Consulting or Advisory Role - Aptar Pharma; Caris Life Sciences; CVS; Guardant Health; Janssen; Oncohost; Orano Med
Patents, Royalties, Other Intellectual Property - We recently filed a patient "DOPED BEO COMPOUNDS FOR OPTICALLY STIMULATED LUMINESCENCE (OSL) AND THERMOLUMINESCENCE (TL) RADIATION DOSIMETRY" (Inst)
Travel, Accommodations, Expenses - Oncohost
 
Joseph Bonventre
Stock and Other Ownership Interests - Autonomous Medical Devices; DxNow; Innoviva; MediBeacon; Oisin; Pacific Biosciences Research Center; Renalytix AI PLC
Honoraria - University of Washington
Consulting or Advisory Role - Mitsubishi Tanabe Pharma; Motric Bio; Praxis Therapeutics; Praxis Therapeutics; Sarepta Therapeutics
Patents, Royalties, Other Intellectual Property - Kidney Organoid Patents assigned to MassGeneralBrigham; KIM-1 Patents assigned to MassGeneralBrigham
 
Toni Choueiri
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; bicycle; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Wenxin Xu
Consulting or Advisory Role - Aveo; Celdara Medical; Deciphera; Eisai; Exelixis; Jazz Pharmaceuticals; Merck; Xencor
Research Funding - ArsenalBio (Inst); Merck (Inst); Oncohost (Inst)